Be a Good Antimicrobial Steward with the QIAstat-Dx
Antimicrobial resistance continues to be one of the major global concerns in treating infectious disease. In fact, experts currently predict that, by 2050, deaths due to antimicrobial-resistant infections will surpass those from cancer. QIAGEN’s QIAstat-Dx syndromic PCR platform provides physicians with valuable diagnostic information which allows them to treat their patients in a more targeted manner. Studies illustrate that syndromic PCR testing for respiratory infections reduces prescriptions of antibiotic treatments. A study from Denmark published in 2022 demonstrated a significant reduction in the number of pediatric patients that were prescribed antibiotic treatment when they were tested using the QIAstat-Dx respiratory panel. Learn more about this innovative platform that can help your lab can do its part to limit the rise of antimicrobial resistance here: QIAstat-Dx
More information about the dangers of antimicrobial resistance, and strategies to support antimicrobial stewardship, can be found at this landing page from our partners at QIAGEN: World AMR Awareness Week